NetworkNewsBreaks Archive - Page 1921 of 1969

MondayFeb 06, 2017 11:15 am

NetworkNewsBreaks – Rosetta Genomics (NASDAQ: ROSG) Receives Two U.S. Patent Allowances for RosettaGx Reveal™ microRNAs

Rosetta Genomics (NASDAQ: ROSG) shares are nudging higher after the company said the U.S. Patents and Trademark Office has granted two patent allowances for divisional patents of the parent application titled “microRNAs and uses thereof.” The company said the patents are important markers for its RosettaGX Reveal™ thyroid cancer assay, as this strengthens its intellectual property portfolio and provides opportunities for monetization. “We are creating a strong intellectual property position in microRNAs and thyroid cancer diagnostics. Of note, there are approximately 500 peer-reviewed publications that confirm the effectiveness of microRNAs as biomarkers in the diagnosis of thyroid cancer which makes…

FridayFeb 03, 2017 3:46 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on February 3, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: AMRS 14.15% – News: Provides highlights of operational and financial results SRAX 6.44% - Appoints private equity investor Derek Ferguson to board of directors and audit committee TGTX 6.52% – News: Law firm files a securities class action lawsuit RWLK 5.95% – News: Law firm announces the filing of a class action lawsuit FNMA 3.08% – News: Announces delisting date from Euro MTF market of the Luxembourg Stock Exchange EARS 2.56% – News: Expands…

FridayFeb 03, 2017 3:44 pm

NetworkNewsBreaks – Soligenix, Inc.’s (NASDAQ: SNGX) SGX301 Receives Promising Innovative Medicine Designation in the UK; Aegis Capital Increases PT to $7

Shares of Soligenix (NASDAQ: SNGX) continued to climb Friday following the company’s announcement yesterday that its SGX301 was granted Promising Innovative Medicine (PIM) designation in the United Kingdom by the Medicines and Healthcare Products Regulatory Agency for the treatment of cutaneous T-cell lymphoma. The PIM designation is the first step toward inclusion in the Early Access to Medicines Scheme (EAMS), which provides severely ill patients with life-threatening and seriously debilitating conditions early access to groundbreaking new medicines - before marketing authorization is approved. "This is now the second of our programs to receive this important designation, with the first being…

FridayFeb 03, 2017 12:22 pm

NetworkNewsBreaks – Amyris, Inc. (NASDAQ: AMRS) Shares Spike 13% on Corporate and Financial Update

Shares of Amyris (NASDAQ: AMRS) are higher after the bioscience company issued an update on certain aspects of its business and financial results for 2016. Amyris reported three key updates: record revenue in both collaborations and product sales for 2016; near-term debt maturities resolved; and the completion of strategic transition out of commodity products. “We are pleased to have achieved a record year of revenue growth, and of having completed all of the 2016 strategic milestones we set out to, and we continue to make good progress on our debt structure by having resolved our near-term debt maturity issues in…

FridayFeb 03, 2017 12:18 pm

NetworkNewsBreaks – Interpace Diagnostics Group, Inc. (NASDAQ: IDXG) Prices $3.6M Public Offering; Shares Tumble

Shares of Interpace Diagnostics Group (NASDAQ: IDXG) are 25% lower in late morning trade after the company priced its public offering of 1.2 million shares of common stock at $3 per share for estimated gross proceeds of approximately $3.6 million. Additionally, the company has permitted the representative of the underwriters an over-allotment option to purchase up to an additional 108,000 shares of its common stock. Interpace said it intends to use the net proceeds of the offering for working capital, repayment of debt and other liabilities, and general corporate purposes. Pending customary closing conditions, the offering is expected to close…

FridayFeb 03, 2017 12:15 pm

NetworkNewsBreaks – FDA Accepts Filing of Intellipharmaceutics’ (NASDAQ: IPCI) NDA for Rexista™; Aegis Reiterates ‘Buy’ Rating and $8 PT

Shares of Intellipharmaceutics International (NASDAQ: IPCI) are slightly higher following news late yesterday that the FDA has accepted the company’s filing of a New Drug Application (NDA) for Rexista™ for the management of moderate to severe pain. Pivotal pharmacokinetic and abuse-deterrent studies have shown Intellipharmaceutics’ Rexista as bioequivalent to OxyContin®. "The acceptance of filing of our NDA for Rexista™ represents an important step towards the commercialization of a potentially best–in-class abuse-deterrent oxycodone hydrochloride extended release product. We look forward to working with the FDA during their review of our NDA submission," Intellipharmaceutics CEO Dr. Isa Odidi stated in the news…

FridayFeb 03, 2017 9:19 am

NetworkNewsBreaks – Social Realty, Inc. (NASDAQ: SRAX) Appoints Derek Ferguson to Board of Directors

Internet advertising company Social Reality, Inc. (NASDAQ: SRAX) this morning announced the appointment of Derek J. Ferguson to its board of directors, effective January 19, 2017. Ferguson will also serve as a member of the company’s Audit Committee moving forward. In total, Ferguson brings more than 13 years of experience as a principle investor in private credit and equity investments to the Social Reality team, notably having worked with Victory Park Capital Advisors, LLC, from February 2012 through July 2016. CEO Christopher Miglino noted this experience, as well as Ferguson’s familiarity with Social Reality, in this morning’s news release. “While…

ThursdayFeb 02, 2017 12:27 pm

NetworkNewsBreaks – Check-Cap (NASDAQ: CHEK) Advances toward Regulatory Approval of Colonoscopy Alternative, C-Scan®

Check-Cap (NASDAQ: CHEK) is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the screening of precancerous polyps and cancer. The company’s C-Scan® system provides an alternative to the current Colorectal Cancer (CRC) screenings, such as a colonoscopy, to help increase screening rates. Unlike a colonoscopy, Check-Cap’s system doesn’t require a bowel prep, which is a huge selling point for at-risk patients. Check-Cap recently enrolled the first patient in its multi-center study of the C-Scan® system in support of its plans to submit for a CE Mark in the first…

ThursdayFeb 02, 2017 12:24 pm

NetworkNewsBreaks – NV5 Global, Inc. (NASDAQ: NVEE) Surpasses Revenue Goals; Secures over $10M in Contracts

NV5 Global (NASDAQ: NVEE) kicked-off 2017 with news that it had surpassed its goal to enter into the New Year with $300 million in annual revenues. The company intends to reach $600 million in annual revenues by 2020, and it was recently awarded over $10 million in contracts with U.S. airports. In addition to a $5 million contract with Dallas Fort Worth International Airport to provide retro commissioning, infrastructure asset condition assessment and other services to modernize the airport's asset portfolio over five years, NV5 was awarded a $5.4 million contract to provide quality assurance testing services at Fort Lauderdale…

ThursdayFeb 02, 2017 12:21 pm

NetworkNewsBreaks – Propanc Health Group Corp. (PPCH) Continues to Advance Pipeline of Anti-Cancer Products

Propanc (OTCQB: PPCH) is a development-stage health care company working to advance its pipeline of new and proprietary treatments for cancer patients suffering from solid tumors toward clinical trials. The company recently issued an update on the progress of additional pending patent applications, noting that it had received a written opinion from the International Search Authority regarding a recent Patent Cooperation Treaty application filed in Australia. The majority of claims in the written opinion were considered novel and inventive, as determined by the authorized officer from the Australian Patent Office. The company’s patent application in Spain, titled "Cancer Treatment," was…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks